Leveraging the Spleen Tyrosine Kinase (SYK) Pathways to Target Inflammatory Signaling in Multiple Diseases with Fostamatinib

Time: 2:30 pm
day: Day Two


  • Treating antibody-mediated platelet destruction with the first kinase inhibitor approved for immune thrombocytopenia
  • Discussing late-stage clinical trial development for autoimmune hemolytic anemia (antibody-mediated RBC destruction)
  • Weaponizing against COVID: discussing the use of fostamatinib in late phase clinical trials for the treatment of hospitalized adults with COVID-19